Filing Details

Accession Number:
0000909012-12-000273
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-05-14 15:19:50
Reporting Period:
2012-05-11
Filing Date:
2012-05-14
Accepted Time:
2012-05-14 14:19:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
897075 Repros Therapeutics Inc. RPRX Biological Products, (No Disgnostic Substances) (2836) 760233274
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman Perceptive Advisors Llc
499 Park Avenue, 25Th Floor
New York NY 10022
No No Yes No
1224962 Perceptive Advisors Llc 499 Park Avenue, 25Th Floor
New York NY 10022
No No Yes No
1249675 Ltd Fund Master Sciences Life Perceptive C/O Perceptive Advisors Llc
499 Park Avenue, 25Th Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-05-11 145,000 $6.35 2,778,060 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2012-05-11 25,000 $6.35 2,803,060 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Footnotes
  1. This Form 4 is being filed by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"), Perceptive Advisors LLC (the "Advisor") and Joseph Edelman. The Advisor serves as investment manager to the Master Fund. Mr. Edelman is the managing member of the Advisor.
  2. This amount reflects the total amount of securities held by the Master Fund immediately following the transaction requiring the filing of this statement. In accordance with Instruction 5(b)(iv) of Form 4, the entire amount of the Issuer's securities held by the Master Fund is reported herein. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.